whose tumors were completely resected, with MR imaging at 24-48 hours, 6 months, 12 months, and 2, 3.5, and 5 years postoperatively. They specifically applied this protocol to cases of GTR, based on risks of delayed recurrence. They did not attempt to stratify tumors on the basis of any histological characteristics, including WHO Grade I versus II.
Further efforts have been made to define histological factors that may help to predict the risk of progression in pediatric low-grade gliomas following resection. Pilocytic histological features, as distinguished from diffuse astrocytic, pilomyxoid, oligodendroglial, or other "low-grade" glial tumors, have a clear association with improved prognosis. 14, 15, 24, 33, 37 Within the category of pilocytic tumors, however, recent work has suggested that histological features typically associated with malignant or aggressive behavior in other tumor types-such as necrosis and elevated mitotic activity-do correlate with worsened progression-free survival. 29 The Ki 67 proliferative LIs of PAs have also been associated with reduced progression-free survival. 5, 11 A recent study by our group similarly implicated pathological variables with the risk of recurrence or progression of PAs. 36 In the current study, we sought to create a rational postoperative surveillance imaging strategy that both emphasizes the initial postoperative surveillance image as a baseline and incorporates histopathological variables for determining the optimal surveillance imaging interval for posterior fossa PAs. We show that the risk of recurrence for patients with cerebellar PAs is low if the following conditions are met: 1) evidence of complete resection on postoperative MR imaging within 48 hours, and 2) lack of nodular contrast enhancement on postoperative MR imaging at 3-6 months. The presence of low Ki 67 and the presence of CD68-positive intratumoral cells are also reassuring.
Methods

Patient Population
The records of 102 patients who had undergone resection of low-grade gliomas at St. Louis Children's Hospital and for whom complete histopathological evaluations were available were reviewed, following approval of the Human Studies Committee at Washington University. From these patients, we identified 52 individuals whose tumor types were PA (WHO Grade I), and whose tumor location was the posterior fossa, the most common location for this tumor type. We then selected 40 patients for whom clinical and radiographic follow-up of > 2 years' duration was available. Patients with neurofibromatosis Type 1 were excluded.
Extent of Resection
Each patient had a documented GTR, which was defined as lack of nodular enhancement on early (within 48 hours of surgery) postoperative MR imaging. In cases in which the surgeon documented GTR, but the imaging showed a residual nodule, this was not considered GTR. On the other hand, if the surgeon did not explicitly document a GTR, but the imaging did not show a nodule, we considered this to be GTR. In 3 patients the presence of a nodular enhancement on postoperative MR imaging prompted a return to the operating room for a repeated resection, which in all 3 cases resulted in GTR that was documented on MR imaging.
Neuroimaging Protocol
Preoperatively, all patients underwent MR imaging in a 1.5-T magnet. Sequences included T2-weighted images and T1-weighted images with and without Gd contrast. Following surgery, all patients underwent postoperative MR imaging within 48 hours (termed "early postoperative MR imaging" for the remainder of this report). As noted above, this early postoperative MR imaging was used in the determination of GTR.
Initial postoperative surveillance imaging was defined as contrast-enhanced MR imaging of the brain 3-6 months postoperatively. A second surveillance study typically occurred 1 year postsurgery. After this point, imaging strategies diverged according to the surgeon's preference; however, patients typically underwent imaging at 1-year intervals thereafter for the duration of follow-up. Recurrence was defined as the development of progressive, nodular en hancement on 2 successive follow-up images.
Pathological Analyses
Histological Testing. Slides were examined for the presence or absence of a biphasic pattern, microcyst formation, Rosenthal fibers, eosinophilic granular bodies, oligodendroglioma-like cytological features, vascular hyalinization, chronic inflammation, microcalcifications, hemorrhage, microvascular proliferation (for example, glomeruloid vessels with multiple lumina and endothelial prominence), necrosis, leptomeningeal invasion, and perivascular pseudorosettes such as those seen more extensively in pilomyxoid astrocytomas. An estimation of nuclear atypia (mild, moderate, severe) and the predominant growth pattern (solid versus infiltrative) was also done. The latter was determined by routine histological testing and neurofilament immunostaining (2F11 clone; Dako Cytomation), the latter to identify entrapped axons, either at the periphery of the tumor alone (mostly solid) or throughout the tumor (mostly infiltrative). In addition to standard histological review, the maximum number of mitoses per 10 consecutive hpfs was determined on a careful search of all available slides.
Immunohistochemistry. Immunostaining for CD68 (Dako, 1:2000) and Ki 67 (MIB-1 [prediluted]; Ventana Medical Systems) was performed at the time of initial diagnostic workup in a subset of cases as part of the routine pathological characterization, and added retrospectively in other lesions for which blocks with sufficient tissue were available. The CD68 was evaluated to identify a prominence of intratumoral microglia/macrophages and was considered positive in cases where > 10% of intratumoral cells were immunoreactive. The MIB-1 (Ki 67) proliferative LI was calculated as a maximal LI by counting the percentage of immunopositive nuclei among 500-1000 nonendothelial cells (1-3 hpfs) within "hot spots" identified on low-magnification scanning. High proliferative in-dices were defined as > 1 mitosis/10 hpfs or > 0.5% MIB-1 LI (based on median values for this sample of tumors).
Statistical Analysis
Recurrence-free survival was defined as the time interval from the date of surgery to the date of recurrence or death, whichever came earlier. Alive or recurrence-free patients as of last contact were deemed censored. Univariate survival analyses were performed to evaluate the associations between demographic, clinical, and pathological variables and RFS. The Kaplan-Meier product limit method was used to estimate empirical survival functions for categorical variables, while the log-rank test was used to test the group difference in survival functions. The Cox proportional hazard model was fitted to assess the association of continuous variables with RFS. Pathological variables with p values < 0.1 were then used as predictors in a further multivariate Cox proportional hazard model analysis. Risk factors that were significant at the 0.1 level in the multivariate model were generally retained for use in a risk stratification model, and a likelihood ratio test was used to compare between nested models. The overall predictive value of the multivariate model was indicated by the C-index of Harrell et al. 19 A recurrence risk score was created by the linear predictor in the final model. The risk score, when compared with the median risk score for the patient set as a whole, enabled us to categorize patients as either high risk or low risk. This risk categorization was then evaluated using a log-rank test and illustrated by generating Kaplan-Meier curves. All tests were 2-sided, and a p value < 0.05 was considered statistically significant. All analyses were performed using R version 2. 
Results
The demographic and clinical findings are listed in Table 1 . In our patient sample, the average follow-up duration was 66.9 months (range 25.2-237.2 months). The first surveillance MR imaging scan was routinely obtained between 3 and 6 months, with an average of 5.3 months. Although no patient had evidence of nodular enhancement on MR imaging within 48 hours of surgery, 13 demonstrated new nodular enhancement, raising concern for residual or recurrent tumor, on their first surveillance MR imaging study at 3-6 months. Of these 13 patients, 10 ultimately went on to develop definitive recurrence, whereas the other 3 showed regression of their nodular enhancement. The 13 patients with nodular enhancement on their first surveillance MR imaging study underwent this test at a mean of 4.92 months, as opposed to 5.68 months for patients with negative results on MR imaging; this difference was not significant (p = 0.137, unpaired t-test).
One additional patient, in whom there was no evidence of nodular enhancement on the initial surveillance MR imaging study, developed a recurrence at 48 months postoperatively. Within the category of patients with nodular enhancement on initial surveillance MR imaging, 1 of these patients actually had initial regression of nodular enhancement over the span of 4 years, followed by redevelopment of nodular enhancement and, ultimately, definitive recurrence at 65 months postoperatively. Another patient underwent close follow-up and was ultimately noted to have the development of a second lesion distant from the first; it was this second lesion that became a definitive recurrence, whereas the first remained stable. We have not, however, classified this patient as having a late recurrence, because a recurrence was suspected after his first surveillance MR imaging study. In total, 11 (27.5%) of 40 patients developed tumor recurrence after resection, with a mean time to recurrence of 16 months and a median of 6.4 months (range 2-48.2 months). A representative series of follow-up MR images are shown in Fig. 1 .
In only 1 case was recurrence symptomatic (headache and difficulty walking). All patients with recurrent tumors underwent further therapy according to accepted treatment protocols: 4, 6, 7, 12, 18, 21, 22, 38 repeat GTR in 9, Gamma Knife radiosurgery in 1, and focal radiation therapy in 1 patient. All of these patients who received additional treatment remain free of disease progression as of their last follow-up. All of the 40 patients we evaluated were alive at the conclusion of the study; of the originally identified group of 52 patients with GTR (that is, including those with < 2 years of follow-up), only 1 died as a result of brainstem involvement (presenting feature of tumor). No demographic variable was associated with recurrence (Table 1) . Nodular enhancement on initial surveillance MR imaging was significantly associated with RFS on univariate analysis (p < 0.0001; log-rank test; Fig. 2) .
We next sought to determine whether any pathological or immunohistochemical variables would provide additional prognostic information ( and where I returns 1 if a subject has CD68 positivity and 0 otherwise. With patients lumped into either high-risk or low-risk groups on the basis of their risk score in comparison with the median risk score, our risk stratification was significantly predictive of RFS (p = 0.0022; log-rank test; Fig. 3 ). The Harrell C-index indicated that the risk score constructed using both Ki 67 and CD68 outperformed Ki 67 alone as a model for recurrence risk (C-index 0.78 vs 0.649). Similarly, we constructed a risk predictor according to the method outlined above, using as our variables both nodular enhancement present on the initial surveillance image and high proliferative index (Ki 67) in the tumor specimen. This model was significantly predictive of RFS (p < 0.0001; log-rank test; Fig. 4) . 
Discussion
Several attempts have been made to develop an optimal postoperative surveillance imaging protocol for pediatric PA. 12, 31, 34, 35 Many neurosurgeons and pediatric neurooncologists consider GTR of PAs as curative, and no further surveillance imaging is warranted. 35 However, cases of tumor recurrence even in the setting of GTR [1] [2] [3] 12, 25, 26, 28, 31 argue against this "no imaging" strategy. On the other hand, frequent surveillance imaging is associated with considerable financial expense, coupled with a psychological burden for patients and their families, who must undergo many years of follow-up before the tumors can be deemed "cured." For these reasons, we sought to combine the first surveillance MR imaging study obtained at 3-6 months postoperatively with specific histopathological features to develop an imaging protocol for predictive risk stratification following GTR.
Our evaluation of the initial surveillance MR imaging studies at 3-6 months postoperatively highlighted several important issues. First, we found that nodular enhancement on MR imaging at 3-6 months was strongly associated with recurrence (p < 0.0001). However, care must be exercised in interpreting this result, because the presence of such enhancement could itself be defined as a residual or recurrent tumor: we identified 3 such patients in whom nodular enhancement regressed on subsequent imaging. The possibility exists, although it is seemingly unlikely, that the nodular enhancement in these patients may represent spontaneous tumor regression, a documented feature of PA. 2, 13, 16, 17, 27, 31, 32 More likely, the nodular enhancement in these 3 cases represented a reactive tissue response that resolved over time. Nevertheless, the presence of nodular contrast enhancement on early postoperative MR imaging (within 3 days postoperatively) is currently the standard method for detecting residual tumor, 31, 35 largely based on the idea that linear enhancement at the margins of a resection occurs within 3-5 days postoperatively, 8 or even as early as 16 hours after resection. 30 Contrary to these findings, recent work has shown that early postoperative MR imaging following PA resection only has a sensitivity of 0.86 and a specificity of 0.5 in diagnosing residual tumor, suggesting that its accuracy is rather poor. This may reflect the propensity for nonneoplastic, surgically manipulated tissues to enhance. For this reason, it has been suggested that waiting until at least 4-6 weeks after surgery may enhance the accuracy of MR imaging.
Based on this latter finding, we focused on obtaining an MR imaging study within the window of 3-6 months postoperatively as a more accurate predictor of residual or recurrent disease. In our study, we used the standard practice of determining GTR on the basis of the early postoperative MR imaging, despite its limitations in this regard. As noted, 13 of our 40 patients had nodular enhancing lesions on their initial (3-to 6-month) surveillance MR images, with 3 of these patients demonstrating regression of their nodules and 10 patients developing progressive disease that prompted therapy. Whether these 13 "positive" surveillance MR imaging results indicated residual or early recurrent disease was not clear without additional follow-up. A potential caveat to consider is that these patients might have been more appropriately classified as near-total or subtotal resections, in which case the "cure rate" of GTR would not be as low as our current results suggest. Our study also identified an additional patient in whom no evidence of enhancement was present on either the early or 3-to 6-month MR images. This patient nevertheless sustained a recurrence in a delayed fashion. These findings highlight the importance of ongoing MR imaging surveillance, even in cases of seemingly unequivocal GTR.
On the basis of this study, we would suggest that the proper role of early MR imaging is to identify the presence of any large, overlooked tumor that necessitates an early return to the operating room for completion resection; intraoperative MR imaging would also serve this role. The discrimination of those patients more likely to suffer recurrence, on the other hand, seems better determined by a delayed MR imaging study-which was obtained in the window of 3-6 months postoperatively at our institution. We do not have sufficient evidence to suggest that obtaining this MR imaging study earlier or later within the 3-to 6-month time window would have any impact on its diagnostic efficacy, and consequently would suggest leaving the timing up to the preferences of the surgeon. Regarding subsequent imaging, in those cases of "positive" findings; that is, nodular enhancement on the 3-to 6-month delayed postoperative MR imaging, we would certainly adhere to the current postoperative surveillance protocol recommended by Saunders et al. 31 However, given that 1 patient in our series developed a late recurrence that was not evident on 3-to 6-month MR imaging, we do not believe relaxing this follow-up imaging protocol would be prudent, even in the case of negative findings on delayed postoperative MR imaging.
A second important element of our study was the effort to incorporate histopathological variables to stratify patients as either high or low risk of recurrence, along with postoperative surveillance MR imaging. Although a recent effort at our institution identified 4 pathological variables associated with increased risk of progression, 36 we found only 2 factors on univariate and multivariate analysis in the current study that correlated with a significantly greater risk of recurrence: 1) high proliferative index (Ki 67), and 2) a general lack of CD68-positive microglia and macrophages. We then sought to create a prognostication method incorporating proliferative index and any other variables that would lead to a more statistically robust risk prediction. To that end, we first used Ki 67 and CD68 together to create a risk score that performed better than Ki 67 alone in predicting recurrence risk. To highlight the value of the first surveillance MR imaging study in assessing recurrence risk, we created an additional risk score in which Ki 67 was used along with the presence of nodular enhancement on the initial surveillance MR image. This risk stratification method outperformed the risk score calculated based on histopathological findings only.
We sought to use these risk stratifications to categorize certain patients as low risk and therefore in no need of surveillance imaging, and other patients as high risk and in need of more frequent surveillance imaging. Unfortunately, the patient in our study who suffered delayed recurrence at 48 months was categorized as low risk by both of our risk score methods. Although this finding confounded our effort to streamline the current recommendations for postoperative MR imaging surveillance, it did highlight the importance of ongoing vigilance in the management of pediatric PAs following GTR.
Importantly, our study serves as further evidence that Ki 67 activity may predict a greater likelihood of disease progression. The Ki 67 LI in PAs has previously been shown to have either a nonsignificant association 11 or a significant relationship 5 with recurrence. In aggregate, this evidence points to a potential role for Ki 67 activity as a prognostic factor following PA resection. The fact that Ki 67 was found to be important only in cerebellar PA and not in our previous study 36 suggests that its importance might be location specific. Future work with larger series will be required to determine whether Ki 67 has unique value for predicting cerebellar PA recurrence and to confirm the prognostic association of new foci of nodular contrast enhancement detected in the 3-to 6-month follow-up MR imaging study.
The negative statistical correlation between the presence of CD68-positive microglia/macrophages and the risk of recurrence is an intriguing finding, but not one for which a clear rationale is apparent. Previous studies have shown that PAs have higher microglial numbers than do highergrade astrocytic tumors. 23 Unpublished studies from our laboratory (D.H.G.) also suggest that PA tumors associated with neurofibromatosis Type 1 have higher microglia numbers than do their sporadic counterparts, which is intriguing in light of their generally more indolent behavior. As stated above, future mechanistic studies will be required to define the role of microglia in pediatric low-grade glioma growth.
9,10
Conclusions
In this report, we found that the presence of nodular tumor enhancement on the initial surveillance MR imaging study had predictive value for recurrent disease, which improved with the incorporation of Ki 67 and CD68 as pathological variables for predicting progressive disease. However, our cases of delayed recurrence of gross-totally resected tumors in purportedly low-risk patients emphasize that the absence of abnormalities on surveillance imaging does not eliminate the risk of developing recurrent disease. Prospective studies will help to refine risk stratification and will allow for the optimization of future postoperative surveillance protocols.
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